S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
NOTICE: Your retirement is in immediate danger (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NOTICE: Your retirement is in immediate danger (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:JUNO

Juno Therapeutics (JUNO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$86.96
$86.96
50-Day Range
$86.96
$86.96
52-Week Range
$19.62
$87.01
Volume
2 shs
Average Volume
5.48 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

JUNO stock logo

About Juno Therapeutics (NASDAQ:JUNO) Stock

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JUNO Stock News Headlines

Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
⚡ 2,467% Return on Israeli Laser Company?
This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.
See More Headlines


JUNO Company Calendar

Last Earnings
11/01/2017
Today
6/10/2023

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
NASDAQ:JUNO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A

Key Executives

  • Howard H. Pien (Age 59)
    Independent Chairman of the Board
  • Hans Edgar Bishop (Age 53)
    President, Chief Executive Officer, Director
  • Sunil Agarwal M.D. (Age 47)
    President of Research & Development
  • Steven D. Harr M.D. (Age 46)
    Chief Financial Officer, Head of Corporate Development
  • Hyam I. Levitsky M.D (Age 54)
    Executive vice president - Research, chief scientific officer
  • Robert W. Azelby (Age 49)
    Executive Vice President, Chief Commercial Officer
  • Ann Lee Ph.D.
    Executive Vice President - Technical Operations
  • Patrick Y. Yang (Age 69)
    Executive Vice President
  • Cynthia Elkins
    Chief Information Officer
  • Bernard J. Cassidy (Age 62)
    General Counsel, Secretary













JUNO Stock - Frequently Asked Questions

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. The firm's revenue was up 115.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.57) earnings per share.

What other stocks do shareholders of Juno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), TherapeuticsMD (TXMD), Incyte (INCY), Alibaba Group (BABA) and Heritage-Crystal Clean (HCCI).

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

What is Juno Therapeutics' stock price today?

One share of JUNO stock can currently be purchased for approximately $86.96.

How can I contact Juno Therapeutics?

Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The official website for the company is www.junotherapeutics.com. The biopharmaceutical company can be reached via phone at +1-206-5821600.

This page (NASDAQ:JUNO) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -